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Ridley [1] acknowledges that two recent studies have
shown that when innovative medicines that provide a
substantive health gain are considered, prices in devel-
oped countries are comparable with those in the
United States [2,3]. He goes on to suggest that price
differentials for follow-on or “me-too” drugs require
further study as these prices are also important for
global pharmaceutical research and development
(R&D), international trade policy, and US government
procurement of pharmaceuticals. We believe there are
a number of assumptions in the debate about prices of
follow-on drugs that deserve challenge.
Both Ridley [1] and Calfee et al. [2] characterize
mechanisms for establishing which pharmaceuticals
will be funded in other countries as “price controls.”
This assertion is not necessarily correct from other
country perspectives. The Australian system is consid-
ered to be about valuing pharmaceuticals and implicit
in that valuation is a judgment about the type of R&D
that is valued. Lower prices for follow-on or me-too
products should be considered a signal to the pharma-
ceutical industry that research in these areas is not
valued as highly.What is perceived as price control may
equally be perceived as the impact ofmarket forces. The
differential which is not acknowledged in the global
debate is the extent to which differences in prices reﬂect
differences between US values and those of other coun-
tries, particularly when the value applies to follow-on
or me-too medicines where the output may be valued
very differently. It is difﬁcult to uphold the argument
that other countries should pay for R&D that the
United States values but other countries may not.
Ridley also highlights the argument that other
countries’ pharmaceutical reimbursement systems are
“slowing the process of drug development worldwide”
[4]. Pharmaceutical R&D expenditure has risen from
approximately $18 billion in 1990 to $37 billion in
2002, proportional to increased sales [5]. Inmost devel-
oped countries, pharmaceutical expenditure has risen at
a faster rate than overall health expenditure [5]. Thus,
pharmaceutical R&D funding is likely to have grown
proportional to health R&D. This contention is
supported by data which show that pharmaceutical
R&Dwas 37%of all health R&D in 1988 in the United
States, Canada, France, Germany, and Japan. By 1997
this had risen to 46% [6]. Given the further increase in
pharmaceutical expenditure since 1997 as a proportion
of all health expenditure, it is likely to be even higher
today. By comparison, pharmaceutical sales only repre-
sent 12–20% of health expenditure [7]. Given these
data it does not seem unreasonable to question whether
we are currently overinvesting in pharmaceutical R&D,
which is not targeting unmet clinical needs.
Finally, the lack of transparency of US prices is
often neglected in these debates. All international
pricing studies that suggest the US prices are higher
should be viewed with caution until US pharmaceuti-
cal prices achieve full transparency. Calfee et al. did
not include rebates in their analysis of US prices and
yet, added rebates to the German prices [2]. Published
data from 2006 show that for 29 of the 43 products
in Calfee et al.’s study [2], Veterans Affairs––Federal
Supply Schedule prices and Big 4 prices were lower
than the Federal Supply Schedule prices. Our study
also found that the US government obtains substantial
discounts even on innovative medicines [3]. Until
prices are transparent, we have no reason to believe
that signiﬁcant discounts are not also available to
pharmacy beneﬁt managers and other large institu-
tional purchasers.
Countries have adopted mechanisms for making
decisions about purchasing and valuing pharmaceuti-
cals not solely in response to future R&D needs, but
also taking into account current population needs. The
Australian reimbursement system, which operates
within the context of the National Medicines Policy
[8], speciﬁcally identiﬁes this objective of balancing the
needs of access for both individuals and communities
with the needs of a viable and responsible pharmaceu-
tical industry. Achieving a balance between health
gains that could be made for the community now and
health gains possible in the future is imperative, but
not well understood and clearly valued differently in
different countries. Very often when the debate focuses
on prices and their putative impact on future R&D,
the effect of high prices on health gains foregone
because of the lack of access is ignored. Health, phar-
maceutical, and trade policies should aim to balance
these needs.
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